Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THB001 in Chronic Cold Urticaria
NCT05510843Phase 1Terminated
- Sponsor
- Third Harmonic Bio
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of THB001 in Cold urticaria (CU) (3 arms), sponsored by Third Harmonic Bio. Primary endpoint: Incidence and severity of adverse events. Started Sep 2022; status: terminated.
02
Drugs
THB001
03
Conditions
Cold urticaria (CU)
Beyond the preview
Go deeper on NCT05510843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510843.